Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMYYB9)

Drug Name
LABP-104 Drug Info
Synonyms NIM-1324
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMMYYB9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting LanC-like protein 2 (LANCL2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Omilancor DM595I9 Ulcerative colitis DD71 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LanC-like protein 2 (LANCL2) TTMK3EX LANC2_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT05019950) A Randomized, Placebo-Controlled, Double-Blind, Single-Center Study to Evaluate Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3 Correction to: Efficacy, Safety, and Tolerability of ?Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 Dec 1;28(12):1938.